Antimikrobno djelovanje nekih glukopiranozil-pirimidin karbonitrila i fuzioniranih pirimidinskih sustava

3-Amino-5-(4-chlorophenylamino)-4-cyanofuran-2-carboxamide (2) was used as the key molecule for preparation of various furo- pyrimidines 3-9 and formation of spiro-cycloalkane furopyrimidines 10, 11. Also, poly fused heterocyclic compounds 13-17 were prepared from compound 2. The synthesized compounds were screened for their antimicrobial activity.3-Amino-5-(4-klorfenilamino)-4-cijanofuran-2-karboksamid (2) upotrebljen je kao ključni spoj za pripravu različitih furo-pirimidina 3-9 i spiro-cikloalkane furopirimidina 10 i 11. Fuzionirani heterociklički spojevi 13-17 pripravljeni su također polazeći iz spoja 2. Sintetizirani spojevi ispitani su na antimikrobno djelovanje

Sinteza i vrednovanje analgetskog, protuupalnog i ulcerogenog djelovanja nekih triazolo- i 2-pirazolil-pirido[2,3-d]-pirimidina

New series of 2-hydrazino-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidines and its 1,7,8,9-tetrahydrocyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidine, 1,7,8,-9-tetrahydrocyclopenta[5,6]pyrido[2,3-d][1,2,3,4]tetrazolo[4,5-a]pyrimidine, 8,9-dihydro-7H-cyclopenta[5,6]pyrido[2,3-d]imidazolo[1,2-a]pyrimidine, 2-(pyrazol-1-yl)-7,8-dihydro-6H-cyclopenta[5,6]pyrido[2,3-d]pyrimidine derivatives were prepared in order to obtain new compounds with potential anti-inflammatory and analgesic activity and low ulcerogenic effect. The compounds possessing potent anti-inflammatory activity were further tested for their analgesic and ulcerogenic activities. Compounds 3-amino-6-(4-aryl)-9-(4-arylmethylene)-cyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (4c), 1-amino-2-methyl-6-(4-aryl)-9-(4-aryl-methylene)-cyclopenta[5,6]pyrido[2,3-d]imidazolo[1,2-a]pyrimidin-5(H)-one (6a), 2-amino-5-(4-aryl)-8-(4-arylmethylene)-cyclopenta[5,6]pyrido[2,3-d]pyrimidine-4(H)-one (9), 2-(3-amino-5-hydroxypyrazol-1-yl)-5-(4-aryl)-8-(4-arylmethylene)-cyclopenta[5,6]-pyrido[2,3-d]pyrimidin-4(H)-one (10a) and 3-thioxo-6-(4-aryl)-9-(4-arylmethylene)-cyclopenta[5,6]pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5(H)-one (13) showed significant analgesic effects. Compound 2-(3-amino-5-hydroxypyrazol-1-yl)-5-(4-aryl)-8-(4-arylmethylene)-cyclopenta[5,6]pyrido[2,3-d]pyrimidin-4(H)-one (10a) was evaluated as the lead compound having higher anti-inflammatory activity (82.8%) than ibuprofen (79.5%) and lower ulcerogenic effect.U radu je opisana sinteza serije 2-hidrazino-7,8-dihidro-6H-ciklopenta[5,6]pirido[2,3-d]pirimidina i njihovih 1,7,8,9-tetrahidrociklopenta[5,6]pirido[2,3-d][1,2,4]triazolo[4,3-a]pirimidinskih, 1,7,8,9-tetrahidrociklopenta[5,6]pirido[2,3-d][1,2,3,4]tetrazolo[4,5-a]pirimidinskih, 8,9-dihidro-7H-ciklopenta[5,6]pirido[2,3-d]imidazolo[1,2-a]pirimidinskih i 2-(pirazol-1-il)-7,8-dihidro-6H-ciklopenta[5,6]pirido[2,3-d]pirimidinskih derivata s potencijalnim protuupalnim i analgetskim te manjim ulcerogenim djelovanjem. Spojevima s izraženim protuupalnim djelovanjem testirano je analgetsko i ulcerogeno djelovanje. Spojevi 3-amino-6-(4-aril)-9-(4-arilmetilen)-ciklopenta[5,6]pirido[2,3-d][1,2,4]triazolo[4,3-a]pirimidin-5(H)-on (4c), 1-amino-2-metil-6-(4-aril)-9-(4-aril-metilen)-ciklopenta[5,6]pirido[2,3-d]imidazolo[1,2-a]pirimidin-5(H)-on (6a), 2-amino-5-(4-aril)-8-(4-arilmetilen)-ciklopenta[5,6]pirido[2,3-d]pirimidin-4(H)-on (9), 2-(3-amino-5-hidroksipirazol-1-il)-5-(4-aril)-8-(4-arilmetilen)- ciklopenta[5,6]-pirido[2,3-d]pirimidin-4(H)-on (10a) i 3-tiokso-6-(4-aril)-9-(4-arilmetilen)-ciklopenta[5,6]pirido[2,3-d][1,2,4]triazolo[4,3-a]pirimidin-5(H)-on (13) pokazali su značajno analgetsko djelovanje. Spoj 2-(3-amino-5-hidroksipirazol-1-il)-5-(4-aril)-8-(4-arilmetilen)-ciklopenta[5,6]pirido[2,3-d]pirimidin-4(H)-on (10a) je vodeći spoj s jačim protuupalnim djelovanjem (82,8%) od ibuprofena (79,5%), a slabijim ulcerogenim djelovanjem

Mapping 123 million neonatal, infant and child deaths between 2000 and 2017

Since 2000, many countries have achieved considerable success in improving child survival, but localized progress remains unclear. To inform efforts towards United Nations Sustainable Development Goal 3.2—to end preventable child deaths by 2030—we need consistently estimated data at the subnational level regarding child mortality rates and trends. Here we quantified, for the period 2000–2017, the subnational variation in mortality rates and number of deaths of neonates, infants and children under 5 years of age within 99 low- and middle-income countries using a geostatistical survival model. We estimated that 32% of children under 5 in these countries lived in districts that had attained rates of 25 or fewer child deaths per 1,000 live births by 2017, and that 58% of child deaths between 2000 and 2017 in these countries could have been averted in the absence of geographical inequality. This study enables the identification of high-mortality clusters, patterns of progress and geographical inequalities to inform appropriate investments and implementations that will help to improve the health of all populations

Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017

A double burden of malnutrition occurs when individuals, household members or communities experience both undernutrition and overweight. Here, we show geospatial estimates of overweight and wasting prevalence among children under 5 years of age in 105 low- and middle-income countries (LMICs) from 2000 to 2017 and aggregate these to policy-relevant administrative units. Wasting decreased overall across LMICs between 2000 and 2017, from 8.4% (62.3 (55.1–70.8) million) to 6.4% (58.3 (47.6–70.7) million), but is predicted to remain above the World Health Organization’s Global Nutrition Target of <5% in over half of LMICs by 2025. Prevalence of overweight increased from 5.2% (30 (22.8–38.5) million) in 2000 to 6.0% (55.5 (44.8–67.9) million) children aged under 5 years in 2017. Areas most affected by double burden of malnutrition were located in Indonesia, Thailand, southeastern China, Botswana, Cameroon and central Nigeria. Our estimates provide a new perspective to researchers, policy makers and public health agencies in their efforts to address this global childhood syndemic

Synthesis, Characterization and Biological Evaluation of Some Quinoxaline Derivatives: A Promising and Potent New Class of Antitumor and Antimicrobial Agents

In continuation of our endeavor towards the development of potent and effective anticancer and antimicrobial agents; the present work deals with the synthesis of some novel tetrazolo[1,5-a]quinoxalines, N-pyrazoloquinoxalines, the corresponding Schiff bases, 1,2,4-triazinoquinoxalines and 1,2,4-triazoloquinoxalines. These compounds were synthesized via the reaction of the key intermediate hydrazinoquinoxalines with various reagents and evaluated for anticancer and antimicrobial activity. The results indicated that tetrazolo[1,5-a]quinoxaline derivatives showed the best result, with the highest inhibitory effects towards the three tested tumor cell lines, which were higher than that of the reference doxorubicin and these compounds were non-cytotoxic to normal cells (IC50 values &gt; 100 μg/mL). Also, most of synthesized compounds exhibited the highest degrees of inhibition against the tested strains of Gram positive and negative bacteria, so tetrazolo[1,5-a]quinoxaline derivatives show dual activity as anticancer and antimicrobial agents

Synthesis and Cytotoxic Effect of Some Novel 1,2-Dihydropyridin-3-carbonitrile and Nicotinonitrile Derivatives

1-(2,4-Dichlorophenyl)-3-(4-fluorophenyl)propen-1-one (1) was prepared and reacted with an active methylene compound (ethyl cyanoacetate) in the presence of ammonium acetate to give the corresponding cyanopyridone 2. Compound 2 reacted with hydrazine hydrate, malononitrile, ethyl bromoacetate and phosphorous oxychloride to afford compounds 4 and 7–11, respectively. The 2-chloropyridine derivative 11 reacted with different primary amines, namely benzyl amine, piperonyl amine, 1-phenylethyl amine, and/or the secondary amines 2-methyl-pipridine and morpholine to give the corresponding derivatives 12–15. Hydrazinolysis of chloropyridine derivative 11 with hydrazine hydrate afforded the corresponding hydrazino derivative 17. Condensation of compound 17 with ethyl acetoacetate, acetylacetone, isatin and different aldehydes gave the corresponding derivatives 18–21. Some of newly synthesized compounds were screened for cytotoxic activity against three tumor cell lines. The results indicated that compounds 8 and 16 showed the best results, exhibiting the highest inhibitory effects towards the three tumor cell lines, which were higher than that of the reference doxorubicin and these compounds were non-cytotoxic towards normal cells (IC50 values &gt; 100 μg/mL)

Synthesis, In Vitro Antimicrobial and Cytotoxic Activities of Some New Pyrazolo[1,5-a]pyrimidine Derivatives

A new series of pyrazole 4&ndash;7 and pyrazolo[1,5-a]pyrimidine 8&ndash;13 were synthesized by using a simple, efficient procedure, and screened for their in-vitro antimicrobial and antitumor activities. Symmetrical and asymmetrical 3,6-diarylazo-2,5,7-triaminopyrazolo[1,5-a]pyrimidine were synthesized by the conventional method and also subjected to microwave irradiation and under ultrasound conditions. The biological results revealed that most of the tested compounds proved to be active as antibacterial and antifungal agents. The antitumor activity of the synthesized compounds was evaluated against human cancer cell lines, MCF-7, HCT-116, and HepG-2, as compared with Doxorubicin as a control